ExaGrid Named a Finalist for the Storage Awards 2023
18.4.2023 15:00:00 EEST | Business Wire | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced that it has been nominated in 13 categories for the 20th annual Storage Awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005066/en/
(Graphic: Business Wire)
ExaGrid has become a finalist in the following categories:
- "One to watch" – Vendor
- Immutable Storage Company of the Year
- Storage Marketing Team of the Year
- Contribution to the Storage Industry – ExaGrid – Paul Mitchell
- Ransomware Protection Company of the Year
- Data Protection Company of the Year
- Enterprise Backup Hardware Vendor of the Year
- Hybrid Storage Vendor of the Year
- Storage Optimisation Company of the Year
- Capacity Storage Vendor of the Year
- Channel Partner Program of the Year
- Storage Product of the Year
- Storage Company of the Year
Voting to determine the winner in each category is underway now and closes on May 31, 2023. Winners of this year’s awards will be announced at “The Storries XX” awards ceremony held in London on June 8, 2023.
“We are pleased to take part in the Storage Awards as it celebrates its 20th year,” said Bill Andrews, President and CEO of ExaGrid. “We are honored to be nominated in so many categories, which include recognition of our channel program and individual members of the ExaGrid Team, as well as our industry-leading Tiered Backup Storage solution.”
Paul Mitchell, ExaGrid Territory Sales Manager in the UK region, said, “I am incredibly honored to be nominated for the ‘Contribution to the Storage Industry’ award and grateful for the recognition. Many thanks to my partners in the channel who are key to success in bringing ExaGrid’s Tiered Backup Storage to our growing customer base, especially in the UK.”
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The Repository Tier offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks.
ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, Iberia, India, Israel, Japan, Mexico, Nordics, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.
Visit us at exagrid.com and connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup storage in our customer success stories. ExaGrid is proud of our +81 NPS score!
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005066/en/
Contact information
Media:
Mary Domenichelli
ExaGrid
mdomenichelli@exagrid.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpZira, Inc. Welcomes Scott Thielman, PhD, as Vice President of Product Development30.6.2026 14:17:00 EEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced that Scott Thielman, PhD, PE, has joined the company as Vice President of Product Development, effective May 1, 2026. Dr. Thielman brings a unique connection to OpZira’s origins. As Chief Technology Officer of Product Creation Studio, he directed the product development of LumiThera’s Valeda® Light Delivery System - the breakthrough photobiomodulation therapy for dry age-related macular degeneration whose acquisition by Alcon led to the creation of OpZira. His involvement with Valeda gives him firsthand knowledge of the science, clinical vision, and engineering decisions that shaped the technology platform from which OpZira was born. For more than 25 years, Dr. Thielman has directed the development of dozens of FDA-cleared medical devices across ophthalmology, neurostimulation, dermatology, urology, and surgical instrumentation, with partners including Olympus
L&T Technology Services Launches Ainfonix ™ 4.0 to Unlock Engineering Intelligence Across Process Industries30.6.2026 13:45:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of Ainfonix™ 4.0, a next-generation Engineering Intelligence platform for process industries. Unveiled at EI Live, LTTS’ flagship event that brings together analysts, industry leaders and engineering experts, Ainfonix™ 4.0 marks an important step in the company’s Enterprise AI and Engineering Intelligence strategy. As industrial enterprises accelerate AI adoption, decades of engineering knowledge remain trapped in fragmented drawings, specifications and technical records across disparate systems. Without trusted and accessible engineering data, organizations struggle to realize the full value of AI, automation and digital transformation initiatives. Ainfonix™ 4.0, developed in LTTS’ Sustainability segment, addresses this challenge by transforming engineering artifacts and multi-modal data into structured, asset-linked information
Klick Health Acquires Oxford PharmaGenesis, Bringing Together Unsurpassed Scientific-to-Commercial Capabilities for Life Sciences Clients30.6.2026 13:03:00 EEST | Press release
Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America. Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick's strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-commercial experience. “We are beyond proud to join forces with Chris, Richard, and the entire team at Oxford PharmaGenesis as we focus on helping life sciences clients think holistically about how evidence, medical strategy, access considerations, and stakeholder engagement connect across the lifecycle with a scientific-to-commercial offer
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma30.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibitor-based chemotherapy-free regimen against standard chemoimmunotherapy in this setting. This pivotal Phase 3 trial builds on the established clinical evidence for BRUKINSA in MCL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “For patients with newly diagnosed MCL, chemotherapy is currently the default. MANGROVE demonstrates for the first time that BRUKINSA plus rituximab, a chemotherapy-free regimen, can deliver unprecedented improvements in progression-free survival, potentially redefining the
Hytera Debuts SC700 Smart 4G Body Camera at CCW 202630.6.2026 12:30:00 EEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, officially debuted its SC700 Smart 4G Body Camera at Critical Communications World (CCW) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630283236/en/ Hytera's latest SC700 Smart 4G Body Camera Public safety operations are increasingly moving toward real-time, connected workflows, where communication, video, and situational awareness are integrated to support a faster and more coordinated response in the field. The SC700 is designed to support this shift. It enables live video, location sharing and push-to-talk communication, helping connect frontline officers with control rooms. Integrated with Hytera HyTalk PoC System, it also supports communication across broadband and PMR users to improve coordination across teams. It also features Intelligent Scene Aware, which can detect abnormal situations such as man down, inactivity, or
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
